PRNewsWire·Sep 8, 2026
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment ConferenceHOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
Compugen's financial profile is defined by extreme volatility, where sporadic milestone payments create temporary profitability, such as the 84.4% net margin observed in 2025Q4. While the company maintains a conservative capital structure with a 0.03 debt-to-e...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | -$0.07+12.5% vs -$0.08 | $3M+102.6% vs $1M |
Q2 2026 May 18, 2026 | -$0.08-14.3% vs -$0.07 | $2M+38.5% vs $2M |
Q2 2026 Mar 2, 2026 | $0.60+957.1% vs -$0.07 | $67M+3018.2% vs $2M |
Q4 2025 Nov 10, 2025 | -$0.07+22.2% vs -$0.09 | $2M+61.9% vs $1M |
HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway materially improves its risk-reward profile. A positive randomized readout could help validate COM701, and it would be a win for CGEN's broader PVRIG approach.
Benchmark CGEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Compugen Ltd. (CGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.49 | $235.44M | 6.55 | 161.14% | 48.57% | 44.84% | — | |
| $4.05 | $2.12B | -2.81 | 26.92% | -945.92% | -50.41% | — | |
| $30.70 | $2.29B | -21.77 | 23.29% | -20.98% | -16.37% | — | |
| $10.71 | $1.81B | -12.75 | -38.24% | -7756.37% | -59.21% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — | |
| $2.95 | $211.06M | -2.09 | — | — | -39.64% | — |
Compugen Ltd. (CGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Compugen Ltd. (CGEN) stock FAQ — growth, dividends, profitability & financials explained
Compugen Ltd. (CGEN) reported $74.0M in revenue for fiscal year 2025. This represents a 2186% increase from $3.2M in 1999.
Compugen Ltd. (CGEN) grew revenue by 161.1% over the past year. This is strong growth.
Yes, Compugen Ltd. (CGEN) is profitable, generating $35.2M in net income for fiscal year 2025 (48.6% net margin).
Compugen Ltd. (CGEN) has a return on equity (ROE) of 44.8%. This is excellent, indicating efficient use of shareholder capital.
Compugen Ltd. (CGEN) generated $31.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
